Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study
| Autor: | María L. Couce, Mattias Rudebeck, Marco Spada, Erik Sparve, Allan M. Lund, Corinne De Laet, Carlo Dionisi-Vici, Ute Spiekerkoetter, Johan Szamosi, Anibh M. Das, Roshni Vara, Manuel Schiff |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Time Factors Adolescent Nitisinone Endocrinology Diabetes and Metabolism medicine.medical_treatment MEDLINE 030209 endocrinology & metabolism Disease Liver transplantation 03 medical and health sciences Neonatal Screening 0302 clinical medicine Endocrinology Internal Medicine medicine Humans Longitudinal Studies Prospective Studies 030212 general & internal medicine Enzyme Inhibitors Child Adverse effect Prospective cohort study Cyclohexanones Tyrosinemias business.industry Infant Newborn Infant Clinical trial Treatment Outcome Child Preschool Nitrobenzoates Female Kidney Diseases Observational study Chemical and Drug Induced Liver Injury business Follow-Up Studies medicine.drug |
| Zdroj: | The Lancet Diabetes & Endocrinology. 9:427-435 |
| ISSN: | 2213-8587 |
| DOI: | 10.1016/s2213-8587(21)00092-9 |
| Popis: | Since the EU approval of nitisinone in 2005, prognosis for patients with hereditary tyrosinaemia type 1 has changed dramatically, with patients living with the disease now reaching adulthood for the first time in history. This study aimed to assess the long-term safety and outcomes of nitisinone treatment in patients with hereditary tyrosinaemia type 1.We did a non-interventional, non-comparative, multicentre study in 77 sites across 17 countries in Europe and collected retrospective and prospective longitudinal data in patients with hereditary tyrosinaemia type 1 who were treated with oral nitisinone during the study period (Feb 21, 2005, to Sept 30, 2019). There were no specific exclusion criteria. Patients were followed-up with an investigator at least annually for as long as they were treated, or until the end of the study. The primary endpoints, occurrence of adverse events related to hepatic, renal, ophthalmic, haematological, or cognitive or developmental function, were assessed in the complete set (all patients already receiving treatment at the index date [Feb 21, 2005] or starting treatment thereafter) and the index set (the subset of patients who had their first dose on the index date or later only).315 patients were enrolled during the study period (complete set). Additionally, data from 24 patients who had liver transplantation or died during the post-marketing surveillance programme were retrieved (extended analysis set; 339 patients). Median treatment duration was 11·2 years (range 0·7-28·4); cumulative nitisinone exposure was 3172·7 patient-years. Patients who were diagnosed by neonatal screening started nitisinone treatment at median age 0·8 months versus 8·5 months in those who presented clinically. Incidences of hepatic, renal, ophthalmic, haematological, or cognitive or developmental adverse events were low. Occurrence of liver transplantation or death was more frequent the later that treatment was initiated (none of 70 patients who started treatment at age28 days vs 35 [13%] of 268 patients who started treatment at age ≥28 days). 279 (89%) of 315 patients were assessed as having either very good or good nitisinone treatment compliance. Treatment and diet compliance declined as patients aged. Suboptimal plasma phenylalanine and tyrosine levels were observed. The majority of patients were reported to have good overall clinical condition throughout treatment; 176 (87%) of 203 during the entire study, 98% following 1 year of treatment.Long-term nitisinone treatment was well tolerated and no new safety signals were revealed. Life-limiting hepatic disease appears to have been prevented by early treatment start. Neonatal screening was the most effective way of ensuring early treatment. Standardised monitoring of blood tyrosine, phenylalanine, and nitisinone levels has potential to guide individualised therapy.Swedish Orphan Biovitrum (Sobi). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|